Overview

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions